Quality of life of patients receiving long-term treatment with first-line disease-modifying drugs: results of a Russian multicenter study using MusiQoL

Results of a multicenter study of health-related quality of life (QoL) measured with the MusiQoL in 534 patients with multiple sclerosis (MS) treated with glatimer acetate (GA) given in subcutaneous injections in dosage 20 mg daily during at least 12 months are presented. The data were compared to those of the multicenter study of 1420 patients treated with interferon-Β (44 mg three times a week). The influence of sex, age and MS duration on QoL was found. There was a significant improvement of QoL after 12 months of treatment with glatimer acetate. Positive changes in some MusiQoL domains were observed in patients treated with interferon-Β after 6 months.